David Christ, MD
Urology · Spencer, IANPI 1922072297
Payments from drug & device makers
Across 60 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$265
- Johnson & Johnson$142
- Endo Pharmaceuticals Inc.$91
- Amgen$91
- Astellas Pharma US Inc$67
- Procept Biorobotics Corporation$47
- plus $309 from 12 others
What the payments were for
- Food & beverage$86385%
- Education$14915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $265 |
| Johnson & Johnson | 5 | $142 |
| Endo Pharmaceuticals Inc. | 7 | $91 |
| Amgen | 5 | $91 |
| Astellas Pharma US Inc | 2 | $67 |
| Procept Biorobotics Corporation | 1 | $47 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Blue Earth Diagnostics | 3 | $39 |
| KARL Storz Endoscopy-america | 2 | $36 |
| Boston Scientific | 2 | $30 |
| Merck | 2 | $29 |
| Coloplast | 2 | $27 |
| Convatec Inc. | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $19 |
| Pfizer | 1 | $14 |
| Bayer | 1 | $13 |
| Endo USA, Inc. | 1 | $13 |
How this compares
$1,012 in reported general payments places this provider in the 40th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 465 | $3,927 |
| Tolterodine Tartrate | 26 | $1,629 |
| Finasteride | 150 | $1,457 |
| Oxybutynin Chloride | 48 | $1,009 |
| NitrofurantoinNitrofurantoin Macrocrystal | 35 | $991 |
| Bethanechol Chloride | 24 | $920 |
| Dutasteride | 35 | $641 |
| Cephalexin | 83 | $605 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 41 | $368 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $303 |
| Ciprofloxacin Hcl | 47 | $261 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $167 |
| Levofloxacin | 22 | $132 |
| Solifenacin Succinate | 11 | $115 |
| Allopurinol | 15 | $113 |
Paid to pharmacies, not to this prescriber.
Other urology in Spencer
- Steven RosenbergUrbandale$1.3M
- Annah VollstedtIowa City$148K
- Karl KrederIowa City$148K
- Vignesh PackiamIowa City$142K
- Michael OdonnellIowa City$128K
- Bradley EricksonIowa City$113K
- Elizabeth TakacsMason City$68K
- Ryan DornbierClive$65K
- Kevin BirusinghDes Moines$59K
- Alexandria HertzIowa City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.